Jessica Merrill

Jessica Merrill

Senior Editor

Brooklyn, NY

Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.

Latest from Jessica Merrill

Jasper’s Briquilimab Stands Up To Competition, But Investors Bail

The company reported positive Phase II data from the BEACON trial testing the c-Kit inhibitor in chronic spontaneous urticaria and said it is planning a Phase IIb/III program.

JPM 2025: Deals, Politics And Parties To Welcome A New Year For Pharma

Politics and policy may get as much attention as deals at the J.P. Morgan Healthcare conference, as this year’s meeting comes just before the inauguration of Donald Trump as US president.

2024 Drug Launches Reflect A Breakout Year For Liver Disease

The year’s new drugs included the first drug approved for non-alcoholic steatohepatitis (NASH) and two drugs for primary biliary cholangitis (PBC).

News In Brief: Sotyktu Phase III Win, Novo’s Alhemo Approval, Axsome Agitation Data, Pfizer Gives Back Sangamo Gene Therapy

BMS's Sotyktu succeeded in two Phase III psoriatic arthritis trials, Novo's Alhemo (concizumab) was approved in the US for hemophilia A and B with inhibitors, Pfizer returned a hemophilia gene therapy to Sangamo ahead of US and EU filings, and more late December news.

Atopic Dermatitis: A Crowded Field With Room To Grow

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Pfizer Confident On Policy Outlook Heading Into Trump Administration

The company updated investors on its 2025 financial guidance and a recent meeting with incoming US president Trump and HHS secretary nominee Robert F. Kennedy, Jr.